Pharmacopeia Scores Another Milestone (PCOP, GSK)

Health and Healthcare

Published: March 18, 2008 6:38 am

Pharmacopeia (Nasdaq: PCOP) has announced that it will receive a milestone payment of $5 million from GlaxoSmithKline (NYSE: GSK), bringing the total received to over $16 million in connection with its ongoing development and commercialization alliance.

The trigger for the additional milestone was Pharmacopeia’s completion of certain early discovery activities under its agreement with Glaxo. This alkso notes that Pharmacopeia is entitled to success-based milestone payments that can total up to $83 million per program for any drug development program pursued through the multi-program alliance. It can also receive up to double-digit royalties on the sales of any products commercialized by Glaxo under the alliance.

Before any pop here, Pharmacopeia had a mere $102 million market cap and had roughly $71.3 million in cash and equivalents on the books, and it also carried $67.3 million in total liabilities.

Jon C. Ogg
March 18, 2008

In 20 Years, I Haven’t Seen A Cash Back Card This Good

After two decades of reviewing financial products I haven’t seen anything like this. Credit card companies are at war, handing out free rewards and benefits to win the best customers.

A good cash back card can be worth thousands of dollars a year in free money, not to mention other perks like travel, insurance, and access to fancy lounges.

Our top pick today pays up to 5% cash back, a $200 bonus on top, and $0 annual fee. Click here to apply before they stop offering rewards this generous.

Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.